Differential Metabolites Before and After Allergen Specific Immunotherapy in Children with Allergic Asthma [0.03%]
儿童过敏性哮喘免疫治疗前后的差异代谢物分析
Yinyan Yue,Menghong Sang,Shuyan Zhang et al.
Yinyan Yue et al.
Background: Asthma is the most common chronic respiratory disease in children. Although conventional treatments such as inhaled corticosteroids and long-acting β2-receptor agonists can effectively control symptoms, some ...
Real-World Response to Dupilumab as Add-on Therapy in Adults and Adolescents with Type 2 Severe Asthma: A Spanish Cohort Study [0.03%]
西班牙成人和青少年2型重度哮喘患者作为附加疗法使用度普利尤单抗的现实世界反应：队列研究
Ana Montoro Ferrer,María Del Mar Moro Moro,Fernando Miguel Parra Borreguero et al.
Ana Montoro Ferrer et al.
Background: Dupilumab has demonstrated efficacy in type 2 severe asthma in clinical trials. Real-world data, particularly from Spain and including patients with prior biologic failure, remains limited. This study evaluate...
Knowledge, Attitudes, and Practices Towards Atopic Dermatitis Among Parents of Children with Atopic Dermatitis: A Cross-Sectional Study [0.03%]
特应性皮炎患儿父母的疾病认知、态度和行为调查——一项横断面研究
Huiwen Zheng,Chen Shen,Dan Xu et al.
Huiwen Zheng et al.
Background: Atopic dermatitis (AD) is a common chronic inflammatory skin disease in childhood that imposes substantial physical and psychosocial burdens on children and their families. However, limited evidence is availab...
Eosinophil-Derived Neurotoxin: A Potential Biomarker for Allergic Bronchopulmonary Aspergillosis [0.03%]
嗜酸性粒细胞源性神经毒素：过敏性支气管肺曲霉病的潜在生物标志物
Minfang Zou,Yun Pan,Yan Yang et al.
Minfang Zou et al.
Objective: Eosinophil-derived neurotoxin (EDN) has emerged as a potential biomarker in asthma. Allergic bronchopulmonary aspergillosis (ABPA) is a severe complication of asthma. This study aimed to investigate serum EDN l...
Disease Burden of Asthma Patients Utilizing Short-Acting Beta-2 Agonist-Only Inhalers as Rescue in the United States [0.03%]
美国仅使用短效β2受体激动剂吸入器作为缓解药物的哮喘患者的疾病负担
Njira Lugogo,Rena C Moon,Yen Chung et al.
Njira Lugogo et al.
Purpose: We aimed to describe the disease burden of asthma and examine relationships between short-acting beta-2 agonist (SABA) use and asthma exacerbations. ...
Safety and Outcomes of Rapid Drug Desensitization to Various Biologic Agents: A Multidisciplinary Experience [0.03%]
快速生物制剂脱敏的安全性及其临床疗效：多学科经验总结
Kutay Kirdok,Elif Ertuna,Umitcan Ates et al.
Kutay Kirdok et al.
Background: Biologic agents are widely used in clinical practice, but hypersensitivity reactions (HSRs) may limit their use. Rapid drug desensitization (RDD) allows patients to safely continue essential therapy by inducin...
Characteristics of Patients with Severe Uncontrolled Asthma in Saudi Arabia: A Cross-Sectional Study [0.03%]
沙特阿拉伯严重难治性哮喘患者的特征：一项横断面研究
Riyad O Al-Lehebi,Rana A Saleh,Abdalla M Alasiri et al.
Riyad O Al-Lehebi et al.
Background: Severe asthma poses significant morbidity and healthcare burden, with the eosinophilic phenotype being particularly prevalent. This study aims to characterize the demographic and clinical profiles of severe eo...
Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study [0.03%]
针对重度哮喘患者医疗补助受益者的研究：Benralizumab可减少加重和费用（ZEPHYR-5研究）
Muhammad Adrish,Jessica K DeMartino,Donna Carstens et al.
Muhammad Adrish et al.
Purpose: Clinical trials have demonstrated benralizumab reduces exacerbations among patients with severe asthma. Evidence on the effectiveness of benralizumab among older adults is limited. The objective was to assess the...
Eosinophilic Organ Complications Associated with Dupilumab Therapy - Narrative Review and Current Evidence [0.03%]
Dupilumab治疗相关的嗜酸细胞性器官并发症-叙事性综述和当前证据
Philipp Suter,Vanessa Alexandra Buetler,Nina Graf et al.
Philipp Suter et al.
Background: Dupilumab is a monoclonal antibody targeting the interleukin (IL) 4 receptor alpha subunit. By inhibiting IL-4 and IL-13 signaling, it has shown efficacy in treating type 2 high inflammatory diseases. While ge...
Feasibility of a 50% Dosing Interval Extension of Anti-IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study [0.03%]
对临床缓解的重度哮喘患者每8周一次抗IL-5生物制剂治疗可行性的真实世界验证研究
Mirna Vergles,Grgur Salai,Neven Tudorić et al.
Mirna Vergles et al.
Background: Initiation criteria for biologic therapies for severe asthma are well established, but guidance on dose reduction or discontinuation remains limited. Sustained clinical remission presents an opportunity to eva...